Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Cipla to acquire 26...

    Cipla to acquire 26 percent stake in AMP Solar Power Systems

    GarimaWritten by Garima Published On 2019-05-24T09:30:01+05:30  |  Updated On 24 May 2019 9:30 AM IST
    Cipla to acquire 26 percent stake in AMP Solar Power Systems

    Cipla will acquire and maintain 26 per cent stake on a fully diluted basis in AMPSolar throughout the term of the power purchase agreement, share purchase, subscription and shareholders agreement and other transaction documents, it added.


    New Delhi: Drug firm Cipla Thursday said it has signed an agreement to acquire 26 per cent stake on a fully diluted basis in AMPSolar Power Systems Pvt Ltd for a cash consideration of up to Rs 12.90 crore.


    AMP Solar Power Systems Pvt Ltd is a wholly owned subsidiary of AMP Solar Technology Pvt Ltd and is a special purpose vehicle formed for the purpose of setting up a captive solar power project in Maharashtra, Cipla said in a filing to the BSE.


    Read Also: Cipla Q4 net profit jumps 133 pc at Rs 357.68 crore; plans fundraising of Rs 6000 crore


    Cipla will acquire and maintain 26 per cent stake on a fully diluted basis in AMPSolar throughout the term of the power purchase agreement, share purchase, subscription and shareholders agreement and other transaction documents, it added.


    The indicative time-period for share purchase is June 12, 2019, it added.


    The company is a multinational pharmaceutical and biotechnology company, headquartered in Mumbai. The company primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.


    It was founded by Khwaja Abdul Hamied as ‘The Chemical, Industrial & Pharmaceutical Laboratories’ in 1935 in Mumbai. The name of the Company was changed to ‘Cipla Limited’ on 20 July 1984. In the year 1985, USFDA approved the company’s bulk drug manufacturing facilities.


    Read Also: Cipla gets no USFDA observations for Indore facility

    agreementAMP Solar Power SystemsAMP Solar Technology Pvt LtdarthritisBSECardiovascular diseaseCipladepressiondiabetesdilutedDrug firm CiplamaharashtraMumbaiNew Delhirespiratoryshares of ciplaSolar power projectstakeweight control
    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok